BioGend Therapeutics Co., Ltd. (TPEX:6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.30
-0.70 (-2.41%)
May 8, 2026, 1:30 PM CST
Market Cap3.52B +10.9%
Revenue (ttm)229.81M +28.0%
Net Income-67.11M
EPS-0.54
Shares Out124.36M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume149,955
Average Volume238,047
Open29.00
Previous Close29.00
Day's Range28.25 - 29.30
52-Week Range27.00 - 49.15
Beta0.15
RSI29.11
Earnings DateAug 7, 2026

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2025, BioGend Therapeutics's revenue was 222.34 million, an increase of 32.62% compared to the previous year's 167.65 million. Losses were -84.61 million, -27.36% less than in 2024.

Financial Statements